Epsilon M&A Deal Report - HRA Pharma Rare Diseases

Transaction Multiples for the Valuation of Private Companies

Esteve Pharmaceuticals > HRA Pharma Rare Diseases

Announced Date : 25 April 2024

Type : Acquisition of Majority Stake

Deal Value : Yes

Acquirer : Esteve Pharmaceuticals

Target: HRA Pharma Rare Diseases

Target Country: France

Sector of activity : Health, Pharmaceuticals & Biotechnology

Business Description :

> HRA Pharma Rare Diseases is specialized in rare and ultra- rare diseas ...

No EMAT : 117378

Transaction multiples available

EV/Sales EV/Gross Profit EV/EBITDA EV/EBIT Eq/PBT P/E Price to Book
Historic
Current

: Multiple available

n.s : Multiple calculated, but not significant

Rating **

Source: Epsilon Research / EMAT

Comparable Transactions

Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1226

Example of comparable transactions on EMAT (same sub-sector):

Date Acquirer Target Country Multiples See details
05/06/2024 Rohto Pharmaceuticals Co MoNo chem-pharm Produkte (Sigmapharm) Austria 0
27/03/2024 Private group led by Carvest, Siparex Capron Podologie France 0

Source: Epsilon Research / EMAT

View Report

This report is accessible on EMAT, the reference database for private company acquisition multiples

Example of EMAT Report : click here

View Complete Report
About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

Sectors covered by our analysts

Studies & indices published by Epsilon Research Register to receive (free) publications updates

EMAT Report

Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

Sign up (free) to receive by e-mail updates on EMAT reports published on your preferred sector.

Subscribe to EMAT database